



NEW

NON-INVASIVE DIAGNOSIS OF CARDIAC VALVE LESIONS

NEW

Evaluation of Valve Lesions by Spectrum
Analysis of Dopple Signatures of bloodflow
through Mitral and Aortic Valves.

Mitral Stenosis and Regurgitation



- * 2 Channel Spectrum
Analyser with CW Doppler
- * High Resolution Full Colour Display
- * Simple Cost Effective Screening
- * On-screen ECG Signal
- * Fibre Optic Recorder Output
- * Independent Gain Controls to accentuate
low amplitude regurgitant flow

doptekTM

Doptek Ltd
Dept CVL1
Terminus Road
Chichester Sussex PO19 2UR
Tel: (0243) 774837

1986 Subscription Rates

Official Journals of American Heart Association

Circulation

A monthly devoted to clinical research and advances in the cardiovascular field.

Burton E. Sobel, M.D., Editor

U.S. \$56
Elsewhere \$72

Circulation Research

A monthly concerned with basic research in the cardiovascular field. Francois M. Abboud, M.D., Editor

U.S. \$86
Elsewhere \$105

Hypertension

A bi-monthly concerned with clinical and basic research in the hypertension field. Edgar Haber, M.D., Editor

U.S. \$55
Elsewhere \$70

Stroke

A journal of cerebral circulation, bi-monthly. H.J.M. Barnett, M.D., Editor

U.S. \$50
Elsewhere \$65

Arteriosclerosis

A journal of vascular biology and thrombosis, bi-monthly. Edwin L. Bierman, M.D., Editor

U.S. \$60
Elsewhere \$75

Recurring Bibliography of Hypertension

Bi-monthly, in cooperation with the National Library of Medicine.

U.S. \$12
Elsewhere \$16

Current Concepts of Cerebrovascular Disease—(Stroke)

U.S. Only*

Modern Concepts of Cardiovascular Disease

U.S.*
Elsewhere \$10

Cardiovascular Nursing

U.S. Only*

*Available through most American Heart Association Affiliates.

All Subscriptions annual—subscriptions accepted at any time. Postage included, airmail rates available upon request. Special discount 50% available to research fellows, interns, residents and medical students in U.S., Canada and Mexico. (Letter from chairperson stating post held and completion date is required to qualify for special discount.)

Orders for **Japan** must go through:

Nankodo Co., Ltd.
42-6 Hongo 3-chome
Bonkyo-ku Tokyo JAPAN

Orders for **Europe** must go through:

Bailliere Tindall
1 St. Anne's Road
Eastbourne, East Sussex
BN21 3UN ENGLAND

Remittances should be made in U.S. funds by check, draft, post office or express money order, payable to:

American Heart Association
7320 Greenville Avenue
Dallas, Texas 75231



American Heart Association
Publishing Office

New Kalten - It Had To Happen

atenolol 50mg

Cardioprotection



Amiloride
Hydrochlorothiazide
Potassium Protection

Prescribing Notes for 'Kalten' and 'Tenormin' LS

DOSEAGE

Hypertension: 'Kalten': 50mg atenolol + 2.5mg hydrochlorothiazide + 2.5mg amiloride hydrochloride as amiloride hydrochloride BP 233mg orally one capsule daily, recommended where monotherapy with beta blocker or diuretic proves inadequate.

'Tenormin' LS: 50mg atenolol orally once a day; some patients may respond adequately to 'Tenormin' low strength LS.

Children: 'Kalten' and 'Tenormin' LS are not recommended for use in children.

Elderly Patients: Dosage requirements for 'Tenormin' LS may be lower, especially in patients with renal impairment.

'Kalten' may be suitable for older patients where higher doses of the constituents are considered inappropriate.

CONTRA-INDICATIONS

'Kalten': Heart block, hyperkalaemia, anuria, acute renal failure, severe progressive renal disease, diabetic nephropathy, blood urea over 10 mmol/l or serum creatinine over 120 micromol/l if not possible to monitor carefully and frequently. In renal impairment additional potassium conserving agents may cause hyperkalaemia. Sensitivity to hydrochlorothiazide or amiloride hydrochloride.
'Tenormin' LS: Heart block.

PRECAUTIONS

Untreated cardiac failure, bradycardia, renal failure, anaesthesia, pregnancy, Disturbed fluid or electrolyte balance. Caution in patients with chronic obstructive airways disease or asthma.

Atenolol modifies the tachycardia of hypoglycaemia. Co-administration with verapamil or Class I antiarrhythmic agents.

Withdrawal of clonidine.

Withdrawal of beta blocking drugs should be gradual in patients with ischaemic heart disease.

In Hypertension



One Daily Low Dose

When faced with the need for extra control

Additional precautions for 'Kalten'

Co-administration with lithium.

Metabolic effects: Measurement of potassium levels is appropriate, especially in the older patient, those receiving digitalis preparations for cardiac failure, taking abnormal diets or potassium diets, or suffering from gastrointestinal complaints.

Caution in metabolic or respiratory acidosis.

Diabetes: 'Kalten' may lower glucose tolerance. Discontinue before glucose tolerance testing. Hyponatraemia and hypochloaemia may occur.

Hepatic or renal impairment: Caution in patients where fluid and electrolyte balance is critical. Hyperkalaemia and hypokalaemia may occur. Discontinue treatment if increasing azotaemia and oliguria occur.

Amiloride may precipitate hepatic encephalopathy, jaundice may occur in cirrhotic patients.

Breast-feeding: Discontinue if 'Kalten' deemed essential.

SIDE EFFECTS

Coldness of extremities, bradycardia and muscular fatigue may occur. Sleep disturbance rarely seen. Rash and dry eyes have been reported with beta blockers - consider discontinuance if they occur.

With amiloride hydrochloride and hydrochlorothiazide gastrointestinal disturbances may occur. Side effects commonly associated with diuretics, dizziness and headache may occur. Skin rashes and blood dyscrasias have been reported.

PRODUCT LICENSE NUMBERS AND BASIC MS COST

'Kalten' Capsules 29 (30 in calendar packs) of 25, £16.20

'Tenormin' LS Tablets 29 (30 in calendar packs) of 25, £13.00

'Kalten' and 'Tenormin' LS are trade marks.

Further information is available on request from the Company
Stuart Pharmaceuticals Limited
Stuart House, 40 Alderley Road, Wilmslow, Cheshire SK9 1BE.
STUART